47th ANNUAL CONFERENCE
American Association of Bovine Practitioners
Albuquerque, New Mexico
September 18-20, 2014
Moraxella bovoculi Problems?

Moraxella bovoculi SOLUTION!

The Addison Autogenous Program

- Complete Diagnostic and Autogenous Support
- Fast Delivery on Initial Order
- Excellent Syringeability
- Exceptional Safety Record

MAXI/GUARD® Pinkeye Bacterin has earned the trust of bovine practitioners as the preferred pinkeye preventative when the disease is caused solely by M. bovis. However, the problem can be caused by the combination of M. bovis and M. bovoculi bacteria. Unfortunately no commercial vaccines provide that coverage. When M. bovoculi is present, your best option is utilizing MAXI/GUARD® along with the Addison Autogenous Program. We can assist you from diagnosing the problem to creating the solution!

From the LEADERS in pinkeye prevention!

Addison Biological Laboratory, Inc.
www.addisonlabs.com
800-331-2530
Facebook/AddisonLabs
# Table of Contents

Estimated prevalence of lameness in 53 Northwest US dairy herds  
_Alea C. Hoffman, John R. Wenz, Jorge Vanegas, Dale A. Moore_ ................................................................. 89

Diverse outcomes of bovine viral diarrhea virus (BVDV) infections in a herd naturally infected during pregnancy—a case study  
_Robert W. Fulton, Grant B. Rezabek, Ryan Grant, Julia F. Ridpath, Lurinda J. Burge_ ........................................... 95

Comparative efficacy of tilmicosin, florfenicol, and florfenicol-flunixin meglumine for treatment of undifferentiated fever in backgrounded winter-placed feedlot calves given tilmicosin metaphylactically on arrival  
_Joyce Van Donkersgoed, John K. Merrill, Steve Hendrick_ .................................................................................. 103

Effects of injectable fat-soluble vitamins and selenium on serum status in young beef calves  
_Carl R. Dahlen, Rob L. Stuart, Bryan W. Neville_ ................................................................................................. 109

Effectiveness of tildipirosin and tulathromycin in the control of bovine respiratory disease in high-risk beef heifers  
_Riccardo Compiani, Gianluca Baldi, Maurizio Bonfanti, Daniele Fucci, Giuliano Pisoni, Stefano Jottini, Siddartha Torres_ ........................................................................................................................................ 114

Effects of timing of chlortetracycline in combination with decoquinate on growth performance, health, and carcass characteristics of feeder steers  
_Daniel U. Thomson, R. Spencer Swingle, Mark Branine, Steven J. Bartle, David A. Yates_ .................................. 120

Case study: Challenges in diagnosing hydrocyanic acid toxicity in cattle  
_Thomas Hairgrove, Ron Gill, Larry Redmon, Monte Rouquette, Gary Warner_ ..................................................... 129

Ergot toxicosis causing death in weaned beef calves  
_Bruce Leuschen, Steve Ensley, Paul Plummer_ .................................................................................................. 134

Comparison of milk production changes in adult Holstein cows vaccinated with a 5-way modified-live virus vaccine containing a _Mannheimia haemolytica_ toxoid versus a 5-way modified-live virus vaccine containing a 5-way _Leptospira_ bacterin  
_Michael D. Kleinhenz, Brian E. Miller, Sjoert Zuidhof, Patrick J. Gorden_ .......................................................... 139

Survival of dairy cattle presumptively suffering from idiopathic pericardial hemorrhage using parenteral dexamethasone or isoﬂuprednone acetate  
_Jerome Gaska, Sheila M. McGuirk, Simon F. Peek_ ................................................................................................ 143

The Michigan State University Food Systems Fellowship Program: Meeting the needs of animal agriculture now and in the future  
_Chelsea Render, Heather Roney, Daniel Grooms_ .................................................................................................. 148

---

## Advertisers

Addison Biological Laboratory, Inc. ............................................................................................................. inside front cover
Elanco Animal Health ................................................................................................................................. 99-102
Merck Animal Health .................................................................................................................................. front of book
Norbrook Laboratories Limited .................................................................................................................. inside back cover, back cover

**Cover photo courtesy of Dr. Pam Ruegg, Madison, Wisconsin.**

The abstracts were translated to French by Guy Beauchamp and revised by Dr. Émile Bouchard.

---

## Notice to Readers

All statements, opinions and conclusions contained in articles in *The Bovine Practitioner* are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.
PRODUCT INFORMATION
NADA 141-334, Approved by FDA.

ZUPREVO™ 18% (tildipirosin)
Injectable Solution for Cattle

ANTIMICROBIAL DRUG
180 mg of tildipirosin/ml. For subcutaneous injection in beef and non-lactating dairy cattle only.

Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

BRIEF SUMMARY: for full prescribing information use package insert.

INDICATIONS: Zuprevo 18% is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni.

WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT TO THE PHYSICIAN.

Avoid direct contact with skin and eyes. If accidental eye exposure occurs, rinse eyes with clean water. If accidental skin exposure occurs, wash the skin immediately with soap and water. Tildipirosin may cause sensitization by skin contact.

For technical assistance or to report a suspected adverse reaction, call: 1-800-219-9286.

For customer service or to request a Material Safety Data Sheet (MSDS), call: 1-800-211-3573. For additional Zuprevo 18% information go to www.zuprevo.com.

For a complete listing of adverse reactions for Zuprevo 18% reported to CVM see: http://www.fda.gov/AnimalVeterinary/SafetyHealth.

DO NOT USE ZUPREVO 18% IN SWINE.
Fetal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre•ruminating calves. Do not use in calves to be processed for veal.

PRECAUTIONS: The effects of Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

Made in Germany
Distributed by: Intervet Inc d/b/a
Merck Animal Health, Summit, NJ 07901 Copyright © 2011, Intervet Inc., a subsidiary of Merck & Co. All rights reserved.
IMPORTANT SAFETY INFORMATION
FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM.

IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.

DO NOT USE Zuprevo™ 18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine.

NOT FOR USE IN CHICKENS OR TURKEYS.
Choose the BRD treatment that gets him back to the pen sooner.
Defeat BRD with Zuprevo™ (tildipirosin), the treatment experts count on for fast-acting, long-lasting results.
Ask your Merck Animal Health representative about Zuprevo. Learn more at merck-animal-health-usa.com.

Choose Confidence. Choose Zuprevo.

Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

The effects Zuprevo™ 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.